Once again Berlin will be the gathering place of distinguished
scientists featuring cutting edge research & development in ADC space.
Antibody-Drug Conjugates(ADCs) are monoclonal antibodies (mAbs)
attached to biologically active drugs by chemical linkers with
labile bonds. By combining the unique targeting of mAbs with the cancer-killing
ability of cytotoxic drugs, ADCs allow sensitive discrimination
between healthy and diseased tissue.
Advances in coupling antibodies to
cytotoxic drugs permit greater control of drug pharmacokinetics and
significantly improve delivery to target tissue. Potent new anti-cancer drugs
can now be used to target cancers while minimizing exposure of healthy tissue.
World ADC Berlin is Europe’s longest running and most detailed antibody-drug
As the industry’s
leading summit for Antibody-Drug Conjugates Development, World ADC Berlin covers
every element of ADCs from discovery, development, manufacturing and clinical.
According to ADC Biotechnology, “ADC summit 2016 in Berlin has proved to be a highly useful tool in
deciphering the latest trends in the field from all aspects of ADC development
and manufacture. This conference is a must for anyone currently working within
the ADC arena or looking to move into this exciting field.”
Now in it’s 7th
year, World ADC Berlin will enable attendees to develop more
clinically effective ADCs. Over 3 days, 56 antibody drug conjugate
experts will divulge their cutting-edge research empowering participants
payloads with differentiated mechanisms of action to meet unmet patients
linker’s chemistry to improve in vivo stability and minimize off
Improve on target
efficacy and solid tumor
penetration with novel antibody formats
their ADC compound and submit a
comprehensive bioanalytical package as part of their IND filing
translate into the clinic by managing ADC
preclinical efficacy over-estimation
endpoints by maximizing your ADCs clinical therapeutic window with latest advancements in dosing regimen
and patient stratification strategies
manufacturing processes and QA/QC testing to ensure batch-to-batch
It is estimated
that more than 300 attendees from 120 organizations take part in this
More than 50% of
participants are directors and project team leaders while around 25% of the attendees
are scientists and academics.
fee is as follows
information, please click here.
Dr. Shima Naghavi,
Director of International Affairs